Cambridge Healthtech Institute’s 2nd Annual
Oncolytic Virus Immunotherapy
Oncolytic virotherapy represents an exciting new area of cancer treatment which exploits a virus’s ability to selectively replicate and kill tumor tissue while stimulating a patient-specific immune response against cancer. Interest in the field is at an all-time high following significant deals by Pfizer, Celgene, Amgen, BMS and Boehringer Ingelheim, however, questions still remain around delivery, product and clinical development, pre-clinical modelling, scale-up, manufacturing and suitable commercial models. CHI’s Second Annual Oncolytic Virus Immunotherapy conference brings together the leading industry and academic leaders to discuss the critical steps driving oncolytic virotherapy forward.
KEYNOTE PRESENTATION: Engineering and Bio-Selection to Optimize an Oncolytic Virus Platform
John Bell, Ph.D., Senior Scientist, Center for Innovative Cancer Research, Ottawa Hospital Research Institute
Tumor Selective HSV-Based Oncolytic Vectors for Treatment of GBM
Paola Grandi, Ph.D., Senior Research Director, Immunology/Virology, Oncorus, Inc.
WO-12, a Multi-Mechanistic Immuno-Oncolytic Therapy
Steve H. Thorne, CSO, Western Oncolytics Ltd.
PeptiCRAd, a Novel Oncolytic Virus-Based Therapeutic Cancer Vaccine
Sari Pesonen, Vice President, Clinical Development, Valo Therapeutics
Synthetic Virology: Redesigning Viruses for Cancer Therapy
Clodagh O'Shea, Ph.D., Associate Professor, Howard Hughes Medical Institute Faculty Scholar
Emerging Investigator: Development of OV Immunotherapy Using a Novel Preclinical GBM Model
Hiroshi Nakashima, Ph.D., Instructor, Neuroscience, Brigham and Women's Hospital
Long-Term Follow-Up in Recurrent High Grade Glioma Patients with Durable Responses Treated with Toca 511 and Toca FC
Asha Das, M.D., Vice President, Clinical Development and Medical Affairs, Tocagen
Talk Title to be Announced
Naomi DeSilva, Ph.D., Clinical Site Educator, Sillajen
A Clinical Update from Turnstone Biologics
Caroline Breitbach, Ph.D., Vice President, Translational Development, Turnstone Biologics
Development of an Attenuated Oncolytic Influenza A Virus Expressing Mycobacterial ESAT-6 Protein
Michael Bergmann, M.D., Ph.D., CMO, Vacthera
Rationale for Using Oncolytic Viruses as the Backbone of Combination Immunotherapy Regimens
Howard Kaufman, M.D., FACS, Surgical Oncologist, Rutgers Cancer Institute of New Jersey
FEATURED PRESENTATION: Developing Tumor-Specific Immunogene (T-Sign) Combination Immunotherapies by Arming the Oncolytic Group B Adenovirus Enadenotucirev
Brian R. Champion, Ph.D., CSO, Psioxus Therapeutics Ltd.
T-Stealth Technology Promotes Synergy between Oncolytic Viruses and Immuno-Stimulatory Agents
Matthew Mulvey., Ph.D., CEO, BeneVir Biopharm, Inc.
What Does It Take to Cure Glioblastoma; Combinations Plus?
Samuel D. Rabkin, Ph.D., Professor, Neurosurgery, Massachusetts General Hospital and Harvard Medical School
Emerging Investigator: Oncolytic Virus Induced Rad51 Degradation: Synergy with Poly(Adp-Ribose) Polymerase Inhibitors in Treating Glioblastoma
Jianfang Ning, Ph.D., Brain Tumor Research Center, Massachusetts General Hospital, Harvard Medical School
For more details on the conference, please contact:
Senior Conference Director
Cambridge Healthtech Institute
For exhibit & sponsorship opportunities, please contact:
Manager, Business Development